Pancreatic Cancer Research

ResearcherUniversity of BernActive in the last 2 years

Martin Wartenberg

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-5378-3825; OpenAlex author ID A5059950545, A5121198402. Sources: OpenAlex.

Their work

Papers
17 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
41
Papers, trials and grants by year

2015: 2 papers · 2016: 1 paper · 2017: 1 paper · 2018: 2 papers · 2019: 1 paper · 2020: none · 2021: 1 paper · 2022: none · 2023: 1 paper · 2024: none · 2025: 4 papers · 2026: 4 papers

Papers 17

  1. Agonistic GITR treatment enhances antitumor immune responses and suppresses tumor progression in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00535-026-02347-y↗
  2. Targeting PI3Kδ suppresses pancreatic cancer by dual disruption of fibrosis and immune evasion. Co-author DOI 10.1016/j.celrep.2026.117188↗
  3. Targeting PI3Kδ suppresses pancreatic cancer by dual disruption of fibrosis and immune evasion. Co-author DOI 10.1016/j.celrep.2026.117453↗
  4. Direct Tumor-Adipocyte Contact as a Prognostic Biomarker in Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.ejca.2026.117035↗
  5. Unveiling the biological side of PET-derived biomarkers: a simulation-based approach applied to PDAC assessment. Co-author DOI 10.1007/s00259-024-06958-6↗
  6. TREM-1 as a novel immunotherapeutic target to treat pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.omton.2025.201034↗
  7. Retraction Note: Expression of E-cadherin repressors SNAIL, ZEB1 and ZEB2 by tumour and stromal cells influences tumour-budding phenotype and suggests heteroge… Co-author DOI 10.1038/s41416-025-02959-w↗
  8. Spatially resolved analysis of TGF/BMP signalling in pancreatic ductal adenocarcinoma by digital pathology identifies patient subgroups with adverse outcome. Last author DOI 10.1186/s12885-025-14751-3↗
  9. Smarcd3 is an epigenetic modulator of the metabolic landscape in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41467-023-35796-7↗
  10. Reproducibility of tumor budding assessment in pancreatic cancer based on a multicenter interobserver study. Co-author DOI 10.1007/s00428-020-02987-2↗
  11. A Multiscale Map of the Stem Cell State in Pancreatic Adenocarcinoma. Co-author DOI 10.1016/j.cell.2019.03.010↗
  12. Tumour budding in pancreatic cancer revisited: validation of the ITBCC scoring system. First author DOI 10.1111/his.13508↗
  13. Integrated Genomic and Immunophenotypic Classification of Pancreatic Cancer Reveals Three Distinct Subtypes with Prognostic/Predictive Significance. Co-author DOI 10.1158/1078-0432.ccr-17-3401↗
  14. MicroRNA dysregulation in the tumor microenvironment influences the phenotype of pancreatic cancer. Co-author DOI 10.1038/modpathol.2017.35↗
  15. PTEN alterations of the stromal cells characterise an aggressive subpopulation of pancreatic cancer with enhanced metastatic potential. Co-author DOI 10.1016/j.ejca.2016.06.013↗
  16. Expression of E-cadherin repressors SNAIL, ZEB1 and ZEB2 by tumour and stromal cells influences tumour-budding phenotype and suggests heterogeneity of stromal … Co-author DOI 10.1038/bjc.2015.177↗
  17. Accumulation of FOXP3+T-cells in the tumor microenvironment is associated with an epithelial-mesenchymal-transition-type tumor budding phenotype and is an inde… Co-author DOI 10.18632/oncotarget.2775↗

Closest collaborators

The 25 strongest of 41 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Beat Gloor · 10 shared papers, 2015–2026 · strength 1.57
  2. Eva Karamitopoulou · 10 shared papers, 2015–2025 · strength 1.02
  3. José A. Galván · 5 shared papers, 2015–2025 · strength 0.59
  4. Alessandro Lugli · 5 shared papers, 2015–2025 · strength 0.54
  5. Aurel A. Perren · 5 shared papers, 2015–2025 · strength 0.52
  6. Steve Robatel · 2 shared papers, 2025–2026 · strength 0.49
  7. Mirjam Schenk · 2 shared papers, 2025–2026 · strength 0.49
  8. Anna Silvia Wenning · 2 shared papers, 2025–2026 · strength 0.48
  9. Konstantin Bräutigam · 2 shared papers, 2025–2026 · strength 0.48
  10. Maciej Garczyk · 2 shared papers, 2026 · strength 0.47
  11. Matteo Rossi Sebastiano · 2 shared papers, 2026 · strength 0.47
  12. Georgia Konstantinidou · 2 shared papers, 2026 · strength 0.47
  13. Max Nobis · 1 shared paper, 2026 · strength 0.25
  14. Ulf Kessler · 1 shared paper, 2026 · strength 0.25
  15. Lara Cavinato · 1 shared paper, 2025 · strength 0.24
  16. Kuangyu Shi · 1 shared paper, 2025 · strength 0.24
  17. Lina Gross · 1 shared paper, 2025 · strength 0.24
  18. Michael Guenther · 1 shared paper, 2026 · strength 0.23
  19. Nic G. Reitsam · 1 shared paper, 2026 · strength 0.23
  20. Steffen Ormanns · 1 shared paper, 2026 · strength 0.23
  21. Bruno Märkl · 1 shared paper, 2026 · strength 0.23
  22. Przemyslaw Grochowski · 1 shared paper, 2026 · strength 0.23
  23. Robert Grützmann · 1 shared paper, 2026 · strength 0.23
  24. Christian P. Pilarsky · 1 shared paper, 2026 · strength 0.23
  25. Erik Vassella · 3 shared papers, 2016–2018 · strength 0.21

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.